CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 4, 2013
Result type: Reports
Project Number: SR0307-000
Product Line: Reimbursement Review

Generic Name: Nebivolol

Brand Name: Bystolic

Manufacturer: Forest Laboratories Canada Inc.

Therapeutic Area: Hypertension

Indications: Hypertension, essential

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 18, 2013

Recommendation Type: Do not list at the submitted price